Bristol-Myers Squibb Announces Appointment of Francis Cuss as Executive Vice President and Chief Scientific Officer, Effective July 1; Elliott Sigal Plans to Retire

Sun Apr 7, 2013 3:00pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130407:nBw075050a

NEW YORK--(Business Wire)--
Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of
Francis Cuss, MB BChir, FRCP, 58, as executive vice president and chief
scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., 61,
retires. Dr. Sigal has served as the company`s chief scientific officer since
2004 and on the company`s Board of Directors since 2011. He will retire from
both positions effective June 30, 2013. Drs. Sigal and Cuss will continue to
work together until that time. 

"Francis is a strong and collaborative leader with broad experience in both
discovery and development," said Lamberto Andreotti, chief executive officer,
Bristol-Myers Squibb. "He has been a key member of our productive R&D team who,
under Elliott's leadership, has delivered our strong portfolio and pipeline. As
our company embarks on the next phase of pipeline execution, this is a natural
time for Francis to lead our R&D team. Having worked closely with Francis since
2010 when I invited him to join my Senior Management Team immediately after
becoming CEO, I know that he can ensure the continuation of both the leadership
and strategy that have been the hallmarks of our success." 

"Elliott has been a key leader in the development and execution of our company`s
strategy to become a BioPharma leader," said Andreotti. "He and his team have
become one of the most productive and innovative R&D organizations in the
industry. Elliott has had a significant impact on the transformation of our
company and, most importantly, on the patients we serve. I am grateful for the
many things that Elliott and I have been able to accomplish together." 

"I am honored to have the opportunity to lead this talented R&D team to fulfill
our mission and find new ways to discover, develop and deliver innovative
medicines for patients with unmet medical needs," said Cuss. 

Dr. Cuss has a strong medical background, and broad experience in both research
and development. Prior to joining Bristol-Myers Squibb, Dr. Cuss led teams in
the successful development and approval of several blockbuster medicines. At
Bristol-Myers Squibb, Dr. Cuss has a proven track record of leading our
company`s research organization to become among the most efficient in the
industry. He has built a high-performing team, and has delivered a
differentiated and innovative early and mid-stage pipeline including making
significant contributions in the advancement of our company`s Hepatitis C and
immuno-oncology portfolios, particularly PD-1. 

Dr. Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug
Discovery, adding responsibility for Discovery Medicine and Clinical
Pharmacology in May 2006. Under Dr. Cuss` leadership, Bristol-Myers Squibb has
consistently been rated a leading research organization based on cycle time,
success rates and costs, having increased discovery output while maintaining a
flat operating budget. Dr. Cuss and his team successfully integrated Adnexus,
Medarex and ZymoGenetics into the research organization, and have driven
innovation in the research operating model, processes and governance. Dr. Cuss
became a member of the company`s Senior Management Team in 2010. Prior to
joining Bristol-Myers Squibb, Dr. Cuss spent 14 years at Schering-Plough and
three years at Glaxo, holding positions of increasing responsibility in
discovery, clinical research and medical affairs in both the U.S. and Europe. 

Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing
physician and held several academic appointments, including as adjunct associate
professor at Jefferson Medical College at Thomas Jefferson University in
Philadelphia. Dr. Cuss received his medical training in the U.K. and holds
medical degrees from Cambridge University. He is also a Fellow of the Royal
College of Physicians and of the Faculty of Pharmaceutical Medicine. 

Dr. Sigal joined Bristol-Myers Squibb in 1997 as vice president of the newly
created department of Applied Genomics. He served as senior vice president,
Early Discovery and Applied Technology, head of Drug Discovery & Exploratory
Development, and senior vice president, Global Clinical and Pharmaceutical
Development, before being appointed chief scientific officer and president of
R&D in 2004. Dr. Sigal has been a member of the company`s senior management team
since 2001, was appointed executive vice president in 2006 and was elected to
the Board of Directors in 2011. 

As a physician, Dr. Sigal`s commitment has always been to the patients who have
and will benefit from the new medicines he and his team have helped the company
deliver. Under Dr. Sigal`s leadership, 14 new products have been brought to
market including medicines to treat diseases including cancer, serious mental
illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, solid organ transplant
rejection, and cardiovascular and metabolic diseases. 

There will be a conference call on April 8, 2013, at 9 a.m. (EDT) when company
executives will address inquiries from investors and analysts. Investors and the
general public are invited to listen to a live webcast at
http://investor.bms.com or by dialing 913-312-0389, confirmation code 6437563. A
replay of the call will be available beginning at noon (EDT) on April 8 through
noon (EDT) on April 23, 2013. The replay will also be available through
http://investor.bms.com or by dialing 402-280-9013, confirmation code: 6437563. 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit www.bms.com or follow
us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
jennifer.mauer@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.